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Intravenous bisphosphonates can cause acute kidney injury;
however, this risk was not found with oral bisphosphonates
in randomized clinical trials with restrictive eligibility criteria.
In order to provide complementary safety data, we studied
the risk of acute kidney injury in a population-based cohort
of 122,727 patients aged 66 years and older discharged from
hospital following a new fragility fracture and no history of
bisphosphonate use in the prior year. Bisphosphonate
treatment was identified within 120 days after discharge and
event rates were measured from 90 days of therapy initiation.
The primary outcome was hospitalization with acute kidney
injury with secondary outcomes of new nephrology
consultation and, in a subset of patients with laboratory
values, acute kidney injury was defined as an increase in
serum creatinine. We identified 18,286 bisphosphonate users
and 104,441 non-users with a mean age of 81 years. Of 5772
patients with laboratory values, 40% had chronic kidney
disease (eGFRo60ml/min per 1.73m2). Overall, there was no
statistically significant difference in the risk of acute kidney
injury among bisphosphonate users compared to non-users
(adjusted odds ratio 1.03), and no significant differences in
other outcomes or in subgroups of patients with baseline
chronic kidney disease. Thus, in this older population-based
cohort, oral bisphosphonate use was not associated with
acute kidney injury.
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Oral bisphosphonate use is common, with almost 200
million prescriptions for osteoporosis worldwide as of
2008.1 With multiple robust trials showing the effectiveness
of etidronate, alendronate, and risedronate, bisphosphonates
are now considered the standard of care for the secondary
prevention of fragility fractures from osteoporosis.2–4
A safety concern with bisphosphonate use is acute kidney
injury. This may be partly explained by the mechanism of
action by which bisphosphonates exert their clinical effect.
Bisphosphonates can either create toxic analogs of adenosine
triphosphate or inhibit the mevalonate pathway leading to
inhibition of cellular activity, apoptosis, and disruption of
the cytoskeleton needed for cell structure.5,6 Mitochondrial
dysfunction has been associated with nephropathy and is
seen in both renal tubular and podocyte cells after bispho-
sphonate use.7–10
In clinical studies with intravenous bisphosphonates,
acute tubular necrosis, and collapsing focal segmental
glomerulosclerosis have been reported.11–13 The injury
appears to be dependent on the concentration and rate of
infusion, implying dose-dependent toxicity.14,15 A total of 72
cases of acute renal failure with intravenous zoledronate were
reported to the United States Food and Drug Administration
(FDA) Adverse Event Reporting System from August 2001 to
March 2003. Many patients received dialysis for severe
acute kidney injury and others subsequently developed
chronic kidney disease.16,17 The FDA updated its warning
about acute kidney injury with intravenous bisphosphonates
in September 2011, citing more cases of kidney injury and
deaths due to kidney failure with this medication.18
Whether there exists a risk of acute kidney injury with oral
bisphosphonate use is less clear. Although the bioavailability
of oral bisphosphonates is low, there is the potential for
accumulation.19 The development of acute kidney injury has
been described in three case reports.20–22 Each of these
patients had significant increases in serum creatinine and
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proteinuria within 1 to 3 weeks of starting alendronate. Their
renal function subsequently improved after the medication
was discontinued. Renal biopsies of two of the cases revealed
acute collapsing focal segmental glomerulosclerosis and acute
granulomatous interstitial nephritis.20,21 Reassuringly, this
risk has not been observed in the largest randomized
controlled trials of oral bisphosphonate use.23,24 However,
patients at highest risk of acute kidney injury, namely the
very elderly and those with chronic kidney disease, were
excluded from these trials. This and a lack of statistical power
to exclude a rare but serious adverse event may have
precluded the observation of acute kidney injury.
To provide complementary safety data, we conducted a
population-based cohort study of older adults after hospital
discharge for a fragility (osteoporotic) fracture. Our goal was
to characterize the risk of acute kidney injury following
incident oral bisphosphonate treatment.
RESULTS
Our cohort consisted of 122,727 patients discharged from
hospital following a fragility fracture, of whom 18,286
(14.9%) were bisphosphonate users and 104,441 (85.1%)
were non-users. In all, 38% of bisphosphonate prescriptions
were for etidronate, whereas 33% and 29% were for
alendronate and risedronate, respectively. The majority of
baseline characteristics were similar between bisphosphonate
users and non-users, with significant differences noted in
Tables 1 and 2. The average age of our cohort was 81 years
and 75% were women. In the subset of the cohort with a
baseline (pre-index date) serum creatinine value (n¼ 5772),
40% had chronic kidney disease defined by an estimated
glomerular filtration rate o60 ml/min per 1.73 m2.
Outcomes are presented in Table 3. In the multivariable
model, a priori risk factors for acute kidney injury were
significantly associated with the primary outcome. This
included the presence of chronic kidney disease, malignancy,
congestive heart failure, older age, diuretic use and use of
agents, which block the renin–angiotensin system (Table 3,
footnote). After adjustment, we found no evidence of an
increased risk of hospitalization for acute kidney injury
within 90 days among bisphosphonate users as compared
with non-users (unadjusted odds ratio 1.32, 95% confidence
interval (CI) 1.09–1.62; adjusted odds ratio 1.03, 95% CI
0.84–1.26). These results were consistent in our sensitivity
analysis when we assessed the outcome at 30 days (adjusted
odds ratio 1.15, 95% CI 0.85–1.56). Similarly, we found no
evidence of higher risk of new nephrology consultation among
bisphosphonate users. In the propensity-matched cohort, there
was no significant difference between bisphosphonate users
and non-users in baseline characteristics or in any of our
outcomes (Supplementary Appendix A and B onlne).
Among 1464 patients with a serum creatinine measured
before and within 90 days of follow-up, we found no
significant association between bisphosphonate use and acute
kidney injury defined by standard criteria (X50% increase in
serum creatinine 23/238 (9.7%) in users vs. 94/1226 (7.7%)
in non-users, P¼ 0.36; X100% increase in serum creatinine
8/238 (3.3%) in users vs. 30/1226 (2.4%) in non-users,
P¼ 0.56; X0.3 mg/dl (26.4 mmol/l) or X50% increase in
serum creatinine 32/238 (13.7%) in users vs. 172/1226
(14.1%) in non-users, P¼ 0.89). In a subgroup analysis, the
presence of chronic kidney disease did not influence the
association between bisphosphonate use and hospitalization
for acute kidney injury (P-value for interaction¼ 0.60;
adjusted odds ratio in chronic kidney disease subgroup
0.99, 95% CI 0.75–1.30).
Table 1 | Characteristics of bisphosphonate users and
non-users
Bisphosphonate
Users Non-users
Number N=18,286 N=104,441
Agea 81 (7.3) 81 (7.9)
Female 15,017 (82.1%) 76,478 (73.2%)b
Rural residence 2473 (13.5%) 16,645 (15.9%)
Income (quintiles)c
1st (lowest) 4187 (22.9%) 23,265 (22.3%)
3rd (middle) 3519 (19.2%) 20,356 (19.5%)
5th (highest) 3408 (18.6%) 19,375 (18.6%)
Fracture location
Hip 8741 (47.8%) 49,187 (47.1%)
Femur shaft 187 (1.02%) 1015 (1.0%)
Forearm 2993 (16.4%) 25,219 (24.2%)b
Humerus 1366 (7.5%) 13,111 (12.6%)b
Pelvis 1910 (10.5%) 8933 (8.6%)
Spine (vertebrae) 3089 (16.9%) 6976 (6.7%)b
Comorbidity
Chronic kidney diseased 5658 (30.9%) 29,110 (27.9%)
Cerebrovascular disease 4124 (22.6%) 24,860 (23.8%)
Peripheral vascular disease 423 (2.3%) 2953 (2.8%)
Coronary artery disease 8117 (44.4%) 47,971 (45.9%)
Congestive heart failure 3872 (21.2%) 22,301 (21.4%)
Cancer 1203 (6.6%) 6842 (6.5%)
Medications
Oral hypoglycemic or insulin 2277 (12.5%) 14,101 (13.5%)
Statins 4426 (24.2%) 20,117 (19.3%)b
b-Blockers 4538 (24.8%) 23,655 (22.7%)
Calcium channel blockers 4910 (26.9%) 24,872 (23.8%)
Potassium sparing diuretics 1320 (7.2%) 7958 (7.6%)
Non-potassium sparing
diuretics
5881 (32.2%) 33,788 (32.4%)
Angiotensin-converting
enzyme inhibitor or
angiotensin receptor blocker
7203 (39.4%) 36,423 (34.9%)
Non-steroidal anti-inflammatory
drugs (excluding aspirin)
2710 (14.8%) 15,924 (15.3%)
aMean (s.d.).
bIndicates a standardized difference between bisphosphonate users and controls
410%. Standardized differences are less sensitive to sample size than traditional
hypothesis tests. They provide a measure of the difference between groups divided
by the pooled s.d.; a value410% is interpreted as a meaningful difference between
the groups.
c1% of patients were missing income information. There was also no significant
difference between the second and fourth income quintiles.
dAs assessed by health-care database codes. See Table 2 for serum creatinine values
and estimated glomerular filtration rate.
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DISCUSSION
The results of this study provide important renal safety
reassurances about a commonly prescribed medication.
In this population-based cohort of over 120,000 older adults,
we found no evidence that oral bisphosphonate use increases
the risk of acute kidney injury. The results also imply that in
older adults, bisphosphonates are underutilized for the
secondary prevention of fragility fracture.
As noted in previous studies, increased concentrations and
rates of infusion of intravenous bisphosphonates can lead to
acute kidney injury by disrupting cell function and
structure.5,6 Although oral bisphosphonates such as alen-
dronate do have a long half-life, the bioavailability iso1%.19
Only about half of the bisphosphonate will then be excreted
unchanged by the kidney (glomerular filtration and active
tubular secretion). Although the other half absorbed into
bone will also reach the kidneys unmetabolized, this is done
very slowly and the elimination half-life of alendronate is
estimated to be 410 years.19 Our study supports the notion
that the limited concentration of oral bisphosphonate that
reaches the renal tissue at a given time does not cause
clinically significant events.
This study also demonstrates the widely acknowledged
care gap in the use of bisphosphonates in the secondary
prevention of fragility fractures in Canada. Most recently, the
Canadian Multicentre Osteoporosis Study noted that over a
10-year period, 42 to 56% of women with incident fragility
fractures failed to be treated with any type of medication to
prevent future fractures. During the first year of the study,
only 22% of women were treated with a bisphosphonate.25
These results are consistent with other studies, which
demonstrate that fewer than 20% of women and 10% of
men receive therapies to prevent further fractures.26
Our study has many strengths. In our province during
the period of interest, we were able to study all patients
aged 65 years or more who were candidates for osteoporosis
pharmacotherapy after hospital discharge for fragility
fracture. These patients were an average of 81 years old and
Table 2 | Renal function in bisphosphonate users and
non-users in subset of patients with baseline (pre-index date)
serum creatinine valuesa
Bisphosphonate
Users Non-users
Number 847 4925
Serum creatinine, median (IQR)
mmol/l 76 (62–94) 79 (65–99)
mg/dl 0.86 (0.70–1.07) 0.90 (0.74–1.13)
eGFR ml/min per 1.73m2,
median (IQR)b
66 (51–81) 66 (50–81)
eGFR category:
X90ml/min per 1.73m2 57 (6.8%) 380 (7.7%)
60–89ml/min per 1.73m2 441 (52.1%) 2588 (52.6%)
45–59ml/min per 1.73m2 200 (23.6%) 1036 (21.0%)
30–44ml/min per 1.73m2 114 (13.5%) 656 (13.3%)
p29ml/min per 1.73m2 35 (4.1%) 265 (5.4%)
Urine dipstick proteinuriac
Negative 49 (87.5%) 369 (87.7%)
0.3 g/l p5 (p7.1%) 36 (8.6%)
X1.0 g/l p5 (p5.3%) 16 (3.8%)
Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aPre-index date outpatient serum creatinine values were available in n=847 users
and n=4925 non-users in the year before study enrolment (also referred to as the
index date). If more than one serum creatinine value was available, the most recent
one before the index date was used. The median time from the pre-index date
serum creatinine measurement and the index date was 52 days. In our jurisdiction, a
pre-index date outpatient serum creatinine is a reasonable stable chronic value, with
most patients showing no appreciable difference with repeat testing three or more
months apart.45
bCalculated via the CKD-Epi equation42—where eGFR=141min([serum creatinine
in mmol/l/88.4]/k, 1)amax([serum creatinine in mmol/l/88.4]/k, 1)1.209
0.993Age 1.018 [if female] 1.159 [if African American].
K k=0.7 for females and 0.9 for males, a=0.329 for females and 0.411 for males,
min=the minimum of Scr/k or 1, max=the maximum of Scr/k or 1.
K Racial information was not available in our data sources and all patients were
assumed not to be of non-African-Canadian race. This was a reasonable
assumption; as of 2006, African Canadians represented o7% of the Ontario
population. Source: http://www12.statcan.ca/census-recensement/2006/dp-pd/
hlt/97-562/index.cfm?Lang=E.
cn=56 users and n=421 non-users had urine protein measurements available in the
year before study enrolment.
Cells sizes of one to five are reported as p5 for reasons of privacy.
Table 3 | Association between bisphosphonate use and outcome
No. of patients
No. of patients
with event
Event rate per
10,000 patients
Unadjusted odds ratio
(95% confidence interval)
Adjusted odds ratioa
(95% confidence interval)
Hospitalization with acute kidney injury (90 days)b
User 18,286 122 66.7 1.32 (1.09–1.62) 1.03 (0.84–1.26)
Non-user 104,441 526 50.3 (reference) (reference)
New nephrology consultation
User 18,286 59 32.3 1.10 (0.83–1.46) 1.08 (0.80–1.44)
Non-user 104,441 306 29.3 (reference) (reference)
Hospitalization with acute kidney injury (30 days)b
User 18,286 58 31.7 1.58 (1.18–2.11) 1.15 (0.85–1.56)
Non-user 104,441 210 20.1 (reference) (reference)
aThe primary outcome (and secondary outcomes) were adjusted for 18 different variables, see Materials and Methods section. A priori risk factors for acute kidney injury that
were significantly associated with the primary outcome included age (per year) (1.02 (1.00–1.03)), presence of chronic kidney disease (as assessed by database codes; 2.09
(1.78–2.47)), congestive heart failure (1.57 (1.31–1.88)), and malignancy (1.54 (1.21–1.97)), and use of non-potassium sparing diuretics (2.08 (1.74–2.50)), and angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers (1.44 (1.21–1.71)).
bAbsolute rates of hospitalization with acute kidney injury are underestimated in our study as database codes have excellent specificity but limited sensitivity for the
detection of this condition.28
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had a higher prevalence of chronic kidney disease compared
with patients in clinical trials. The study was made possible
by universal health-care benefits available to all older Ontario
citizens. It is reassuring that our results are consistent with
observations made from randomized controlled trials done
with multiple formulations of oral bisphosphonates.23,24,27
The large number of patients and events in our study
provided good precision around the provided estimates.
We confidently ruled out a twofold or higher risk in acute
kidney injury based on the CI of the primary outcome. As
emigration rates from the province of Ontario are o1% per
year, our follow-up was complete for all patients in the cohort.
Our study does have some limitations. The provincial
drug plan database only records drug dispensing, and we do
not have information on actual drug administration and
patient adherence. Non-adherence to bisphosphonate treat-
ment could bias our findings toward a null effect, although it
is unlikely this explains our observed result. We did not
observe a difference in event rates after 30 days of treatment,
when medication adherence might be expected to be better.
As this was an observational study, the administration of
bisphosphonates was not randomly assigned. Thus, we can
only establish the lack of an association rather than the lack
of a causal relationship. There may have been important
baseline differences between bisphosphonate users and non-
users, which explain our findings. However, it is reassuring
that measured patient characteristics between the two groups
were largely similar. As well, we adjusted for available baseline
characteristics in multivariable analyses, and demonstrated
the findings were robust in a propensity-matched analysis.
Our primary outcome was based on administrative health-
care database codes rather than prospective data collection
with independent outcome adjudication, and thus is less
robust than well-designed prospective studies. These codes
also lack sensitivity but the specificity of the codes used for
our outcome definition has been well validated.28,29 However,
analyses done in a subset of patients with serum creatinine
values provided the same result to that done with database
codes. Finally, if we take those with baseline creatinine values
as representative of our entire cohort, then o5% of our
patients had an estimated glomerular filtration rate o30 ml/
min per 1.73 m2. As such patients with little renal reserve are
at high risk of acute kidney injury, bisphosphonates may or
may not be as safe in this subset of patients.30,31
In conclusion, in this older population-based cohort we
found no evidence of an association between oral bispho-
sphonate use and acute kidney injury. These results support
the short-term renal safety of this common medication.
MATERIALS AND METHODS
Design and setting
We conducted this population-based cohort study using linked
health administrative databases in Ontario, Canada. Ontario
currently has about 13 million residents.32 Residents have universal
access to hospital care and physician services, and individuals aged
65 and older receive universal drug coverage. We conducted this
study according to a pre-specified protocol, which was approved
by the research ethics board at Sunnybrook Health Sciences Centre
(Toronto, Ontario, Canada).
Data sources
We ascertained individual characteristics, covariate information,
drug use, and outcome data from records in eight databases. The
Canadian Institute for Health Information Discharge Abstract
Database (CIHI-DAD) records detailed diagnostic and procedural
information for all hospitalizations in Ontario. Similarly, the
Same-Day Surgery Database (CIHI-SDS) records information for
all same-day surgeries. The Ontario Health Insurance Plan database
contains all health claims for inpatient and outpatient physician
services. The Ontario Registered Persons Database contains demo-
graphic and vital status information on all Ontario residents.
The Ontario Drug Benefit Plan database contains highly accurate
records for all outpatient prescriptions dispensed to patients 65
years of age or older.33 Data on visits to the emergency department
are recorded in CIHI’s National Ambulatory Care Reporting System.
These databases have been used extensively to research health
outcomes and health services, and are virtually complete for all
variables used in this study.34–36 For a subset of patients, serum
creatinine values were available from Gamma-Dynacare, the largest
provider of outpatient laboratory services to residents in south-
western Ontario and from CERNER, the electronic medical record
used in 11 hospitals in southwestern Ontario (outpatient, emergency
room, and inpatient hospital values). These data sets were held
securely in a linked, de-identified form and analyzed at the Institute
for Clinical Evaluative Sciences.
Participants
We established a cohort of all Ontario residents aged 66 or older
discharged from hospital with evidence of fragility fracture (defined
in Supplementary Appendix C online), who were dispensed at least
one medication of any type as an outpatient in the subsequent 120
days. Drug dispensing 120 days after fracture was chosen to account
for any delay in bisphosphonate initiation after hospitalization.
Patient selection is presented as a flow diagram in Supplementary
Appendix D online. Patients were accrued from 1 January 1996 to 31
December 2009. Fragility fractures could be located at any of the
following sites: hip, femoral shaft, forearm, humerus, pelvis, and
spine (vertebrae). For those with evidence of an oral bisphosphonate
(etidronate, alendronate, and risedronate) in the 120 days following
fragility fracture, the date of this prescription served as the start date
for follow-up and was designated the index date. Individuals with
no such prescription in the 120 days after fragility fracture were
deemed to be bisphosphonate non-users, and an index date was
randomly assigned according to the distribution of index dates in
bisphosphonate users. Residents with evidence of more than one
fragility fracture in follow-up were only counted at the time of their
first fracture. Additionally, we excluded patients with evidence of
any bisphosphonate use in the year before index date, evidence of
more than one bisphosphonate prescription on the index date, and
those with evidence of end-stage renal disease in the 5 years before
index date. We excluded individuals who died between their fracture
date and index date, as well as those with evidence of rehospitaliza-
tion during this same period.
Outcomes
We followed patients for 90 days after their index date for outcomes
of interest. We chose 90 days to focus on acute events, and to avoid
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crossovers that could occur in bisphosphonate exposure with longer
periods of follow-up. For example, about a third of patients are no
longer adherent 6 months after starting a bisphosphonate.37
Another reason for choosing 90 days is that prescriptions covered
by the provincial drug plan are prescribed at no 4100-day intervals.
Our primary outcome was hospitalization with acute kidney
injury (Supplementary Appendix E online). We also considered a
secondary outcome of new consultation with a nephrologist (either
as an inpatient or outpatient without a prior history of nephrology
consultation in the past 5 years). In sensitivity analysis, we restricted
the follow-up to the first 30 days.
In the subset of patients with serum creatinine measurements
taken before and after the index date, we assessed for the
development of acute kidney injury based on evidence of a
follow-up serum creatinine value 450% and 4100% the pre-index
date value, respectively. This corresponds to the thresholds used in
the first two categories of acute kidney injury (risk and injury stages)
in the RIFLE classification system.38 Additionally, we assessed for
a follow-up serum creatinine value either at least 0.3 mg/dl
(26.4mmol/l) or 450% the pre-index date serum creatinine value.
This corresponds to the threshold used in the first stage of acute
kidney injury in the AKIN classification system.39 These widely used
definitions were chosen as they have been shown to correlate with
prognosis.40,41 In the subset of patients with pre-index date serum
creatinine values, we estimated glomerular filtration rate using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi)
equation.42
Statistical analysis
We compared the baseline characteristics of bisphosphonate users
and non-users using standardized differences.43,44 This metric
describes differences between group means relative to their pooled
s.d. Differences 410% are considered meaningful.
We used multivariable logistic regression models to estimate the
odds ratio and 95% CI for the association between bisphosphonate
use and each of our outcomes using bisphosphonate non-users as
the referent group. We adjusted for the following: age, sex, year of
index date, fracture location; evidence of a prescription for non-
steroidal anti-inflammatory drugs, angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers, oral hypoglycemics or
insulin, HMG Co-A reductase inhibitors (statins), b-adrenergic
blockade agents (b-blockers), calcium channel blockers, potassium
sparing diuretics, non-potassium sparing diuretics (120 days before
index date); and evidence of chronic kidney disease, cerebrovas-
cular disease, peripheral vascular disease, coronary artery disease,
congestive heart failure, and cancer (5 years before index date and
as defined by administrative codes). In addition, we used a greedy
matching algorithm where we matched bisphosphonate users and
non-users in a 1:2 fashion based on age, sex, index date, and
propensity score. Propensity scores were derived from multi-
variable logistic regression analysis with bisphosphonate exposure
as the dependent variable. We used all other adjustment variables
as previously described to derive the propensity score. We used w2
analyses for the outcome of acute kidney injury defined by a serum
creatinine values. Owing to the small number of patients and
events we did not perform adjusted analyses. Chronic kidney
disease is strongly associated with acute kidney injury, and
therefore we examined whether the odds ratio between bispho-
sphonate use and our primary outcome differed in this sub-
group.30,31 We conducted all analysis with SAS software version 9.2
(Cary, NC).
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